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Objective: NMO and ATM are intertwined both clinically and pathologically. Apolipoprotein (apo) A-I, the main
apolipoprotein of HDL, plays an important role in lipid metabolism in the cerebrospinal fluid and is known to
suppress pro-inflammatory cytokines generated by activated T cells in some autoimmune diseases as an immune
regulator. However, the differences in the levels of serum apoA-I between NMO and ATM patients are unclear.
Methods: In the present study, serum apo A-I levels were measured in 53 NMO patients, 45 ATM patients and 49
healthy subjects. We tested serum apoA-I levels in all participants and investigated EDSS scores of patients with
NMO and ATM. Statistical analyses were performed by using SPSS statistical software.
Result: We found that serum apoA-I levels in patients with NMO were significantly lower in comparison to those
with ATM. We also found that serum levels of apoA-I was lower in male subjects in comparison to the female
subjects in all groups although these differences were not statistically significant in patients with NMO or ATM. It is
also shown in our study that serum apoA-I levels in patients with NMO were significantly elevated after receiving a
high dosage of intravenous corticosteroids over a period of one week. However, we did not find any correlation
between the apoA-I levels and disease disability.
Conclusion: From this study, we concluded that serum levels of apoA-I were lower in NMO patients compared to
patients with ATM. Serum apoA-I studies might provide some useful clues to differentiate NMO cases from ATM
cases.
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Neuromyelitis optica (NMO), as a rare autoimmune
demyelinateting disorder, arouses inflammatory lesions
in the optic nerves and spinal cord and causes some ser-
ious clinical symptoms such as blindness and paralysis. In
NMO, the inflammatory profile primarily involves eosino-
phils/neutrophils and autoantibody reaction. At present,
an autoantibody (NMO IgG) against aquaporin-4 (AQP4),
a water channel expressed on astrocytes, has been incrimi-
nated as a causative factor. Similar to other autoimmune
diseases, Th17 cells and their effective cytokines (such as
interleukin 6) participate in the pathogenesis of NMO
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stated.a demyelinating, inflammatory, and infectious myelopathy,
with a variety of clinical manifestations, including those
associated with multiple sclerosis (MS) [3], NMO [4],
systemic autoimmune disease [5], infection [6], as well
as cases with no specific origin(idiopathic ATM) [7]. Al-
though acute transverse myelopathy can be presented in
a variety of ways and involves pyramidal, sensory, and
autonomic dysfunction to varying degrees, the signs and
symptoms of myelopathy do not provide an insight into
the etiology and the differential diagnosis of the disease.
Therefore, there is a requirement for potential-molecular
markers to differentiate ATM from other demyelinating
and inflammatory myelopathies, including MS, NMO,
other systemic inflammatory diseases (SLE), acute dissem-
inated encephalomyelitis, and postvaccinial myelitis [8].
This article emphasizes the differential diagnoses between
NMO and ATM. Despite the reported differences,
NMO and ATM are still intertwined both clinically andLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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ation of MS and NMO. Thus, it will be very useful if
plasma-based biomarkers can be identified to discriminate
NMO from ATM.
Apolipoprotein (apo)A-I, as the main component of
high density lipoprotein (HDL), plays a vital role in re-
verse cholesterol transportation by facilitating the bind-
ing of HDL and lecithin cholesterol acyltransferase [9].
The central nervous system is the most lipid-rich organ
and approximately 25% of the total body’ cholesterol is
distributed in the central nervous system [10]. It has
previously been shown that apoA-I has been implicated
in several antiatherogenic functions, including protec-
tion against thrombosis and oxidative stress [11]. Beyond
that, apoA-I can protect hippocampal neuronal cultures
from amyloid beta-induced neurotoxicity as well [12].
Moreover, apoA-I might play the role of a constitutive
anti-inflammatory factor [13]. Therefore, the aim of this
study was to evaluate the differences in serum apoA-I
levels between patients with NMO and ATM.
Patients and methods
Serum samples were collected from 147 individuals who
had been treated from January 1, 2006 to December 31,
2012 in the Third Affiliated Hospital of Sun Yat-Sen
University, Guangzhou, China. These patientscomprised
of 53 patients with NMO, 45 patients with ATM and
49 healthy subjects. Demographic and EDSS scores of
NMO and ATM patients and healthy control (HC) group
were presented in Table 1. All NMO patients were di-
agnosed with NMO according to the diagnostic criteria
in 1999 [14] and had been in hospital for the first onset
(n = 40) or acute relapse (n =13). All the ATM patients
were included according to a modified version of the
Transverse Myelitis Consortium Working Group cri-
teria [15]. 45 patients were with a first episode of ATM
and had excluded a compressive etiology. All patients
were scored by the Expanded Disability Status Scale
(EDSS). The mean EDSS score was 4.6 ± 2.0 in NMO
patients and 5.0 ± 2.7 in ATM patients.
All selected patients had never received steroids or
statins treatments or disease-modifying immunosuppres-
sive therapy that can affect the serum apoA-I levels twoTable 1 Demographic and clinical characteristics of NMO,
ATM patients and healthy control group
Patients NMO (n = 53) ATM (n = 45) HC (n = 49)
Male 17 29 25
Female 36 16 24
Range of ages (y) 8–70 5–66 9–70
Means of ages (y) 38.2 39.0 41.0
EDSS 4.6 ± 2.0 5.0 ± 2.7months before admission. The blood was collected to
detect serum apoA-I after overnight fasting. Serum
apoA-I levels were measured by routine clinical testing.
This study was approved by the Ethics Committee of the
Third Affiliated Hospital of Sun Yat-Sen University
(200733) and in compliance with the Helsinki Declar-
ation. All subjects gave informed consents to participate
in this study.
Statistical analysis
All statistical analyses were performed using the Statis-
tical Program for Social Sciences (SPSS) statistical soft-
ware (version 11.0, Chicago, IL, USA). All the data in
this study were presented as means ± SD. Statistical sig-
nificance was set at P < 0.05. The effect of age on serum
apoA-I levels of different groups were analyzed by covari-
ance analysis. The comparison of serum apoA-I levels
among the NMO, ATM patients and the HC group was
performed using covariance analysis with age as the co-
variant. Since serum apoA-I levels can be moderated by
estrogen levels, the patients were divided into two sub-
groups according to the gender. Covariance analysis was
also used to compare serum apoA-I levels of males and fe-
males patients with NMO, ATM or in HC group with age
as the covariant. Correlations between serum apoA-I and
EDSS scores of NMO and ATM patients were analyzed by
Spearman correlation analysis.
Results
In this study, significant differences were found in the
levels of serum apoA-I, depending on the disease type
and gender. Firstly, apoA-I levels in different disease
groups were compared without consideration of gender
and age factors. The results showed that the serum apoA-I
levels in NMO (1.20 ± 0.21 g/L) and ATM (1.32 ± 0.22 g/L)
disease were significantly lower than the levels measured
for healthy controls (1.59 ± 0.13 g/L). Patients with NMO
(1.20 ± 0.21 g/L) had significantly lower serum apoA-I
levels in comparison to patients with ATM (1.32 ± 0.22 g/L)
(Table 2).
In order to assess the influences of gender on serum
apoA-I levels, we made a comparison between male and
female patients on serum apoA-I in each disease group
and healthy group. For NMO and ATM patients, male
patients had lower apoA-I levels than female patients
though the differences were not statistically significant.
The serum apoA-I levels were much higher in female
HC group (1.67 ± 0.21 g/L) than in the corresponding
male HC control (1.52 ± 0.16 g/L) (p < 0.001) (Figure 1).
Furthermore, we compared with male and female pa-
tients respectively (Table 3). The results suggested that
female NMO patients (1.21 ± 0.23 g/L) had the lowest
serum apoA-I level and female HC group (1.67 ± 0.21 g/L)
had the highest serum apoA-I levels (Figure 2). Female
Table 2 Analysis of serum apoA-I among the patients with NMO and ATM and healthy control
Group Gender ratio (female: male) Means age ± SD (years) ApoA-I (g/L) p1 p2 p3
NMO 36:17 38.2 ± 14.4 1.20 ± 0.21 0.006*
ATM 16:29 39.0 ± 16.1 1.32 ± 0.22 <0.001**
HC 24:25 41.0 ± 17.7 1.59 ± 0.13 <0.001**
Data are means ± SD. p1, NMO versus ATM; p2, ATM versus HC; p3, NMO versus HC.
*Difference is significant below the 0.01 level.
**Difference is significant below the 0.001 level
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levels than female ATM patients (p = 0.001). Similarly,
Male patients with NMO had significantly lower serum
apoA-I levels than male patients with ATM (p = 0.002)
(Figure 3). The serum apoA-I levels of male patients in
both NMO and ATM groups were significantly lower than
those in the the healthy controls. To sum up, serum
apoA-I levels was lowest in male NMO patients and
highest in female HC group in this study.
Finally, we explored the correlation between apoA-I
levels and EDSS scores of patients with NMO and ATM
and the changes of serum apoA-I levels in NMO pa-
tients who received a high dose intravenous corticoste-
roids treatment for one week. We found a negative
correlation between the apoA-I levels and EDSS scores
in NMO patients although the correlations showed no stat-
istical differences. Serum apoA-I levels were significantlyFigure 1 Gender influence on serum apoA-I levels within
each group.elevated after receiving high dosage of intravenous corti-
costeroids for one week (Figure 4).
Discussion
Our research showed that the serum apoA-I levels in
NMO and ATM were significantly lower than those in
healthy group. Although the exact reason for these dif-
ferences remained unknown, the following evidences
may explain this phenomenon. It is well-known that
multiple factors are involved in the development of their
pathological process, such as genetic susceptibility, gender
and environment. The autoimmune-inflammation reac-
tion was believed to play a critical role in such process.
The immune-inflammation reaction was characterized by
the infiltration of immune-inflammatory cells and plasma
factors into the lesion site to eradicate infection and to re-
pair damaged tissues [13]. Contact-mediated activation of
monocytes by stimulated T lymphocytes acted as a major
stimulus, triggering the production of large amounts of
tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1
β) which played an important role in chronic inflamma-
tion [16]. ApoA-I, as a specific inhibitor of cytokine pro-
duction in monocyte-macrophages upon contact with
stimulated T cells, exerted most of its inhibitory activity
by specifically binding the activating factor on stimulated
T cells, consequently blocking the interaction between T-
lymphocytes and monocytes [17]. Therefore, apoA-I was
known as a negative acute-phase protein and might dif-
fuse into the extra-vascular compartment and interfere
with the cross-talk between cells in acute or chronic in-
flammation [16], resulting in a decrease of serum apoA-I
levels. In addition, the maintenance of inflammation in a
particular target tissue would in turn keep up a low con-
centration of apoA-I at the systemic level and thus be
beneficial to the production of inflammatory cytokines
[18]. This could account for a significantly lower serum
apoA-I levels in NMO and ATM patients in comparison
to the corresponding serum apoA-I levels in the healthy
group. This also implied that apoA-I may be a sign of the
possible development of inflammation. ApoA-I level was
decreased in the plasma of rheumatoid arthritis (RA) pa-
tients. However, it was enhanced in synovial fluid of RA
patients. It has been reported that ApoA-I also exists in
human cerebrospinal fluid [19]. Therefore, we need to
Table 3 Serum apoA-I levels in male and female NMO, ATM patients and healthy controls
Female ApoA-I (g/L) Male ApoA-I(g/L) p1 p2 p3
Age Age
NMO 38.1 ± 13.2 1.21 ± 0.23 38.5 ± 17.3 1.17 ± 0.17 0.001*a 0.002*a 0.471
ATM 39.8 ± 16.1 1.43 ± 0.22 38.6 ± 16.4 1.34 ± 0.19 0.001*b <0.001**b 0.056
HC 39.3 ± 18.7 1.67 ± 0.21 42.5 ± 16.8 1.52 ± 0.16 <0.001**c <0.001**c <0.001**
Data are means ± SD. p1, Compared serum apoA-I levels among three female groups; p2, Compared serum apoA-I levels among three male groups; aNMO versus
ATM; bATM versus HC; cNMO versus HC; p3, Compared serum apoA-I levels between female and male NMO patients, and female and male patients in other
two groups.
*Difference is significant below the 0.01 level.
**Difference is significant below the 0.001 level.
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ATM in the future.
In this study, another notable finding was the signifi-
cantly lower serum apoA-I levels in patients with NMO in
comparison to those with ATM. Although the reason is
still unclear, it may be associated with the following fac-
tors. Several reports indicated that humoral immunity
participated in the pathogenesis of NMO [20]. The discov-
ery of NMO IgG, which is directed against aquaporin-4
(AQP4), is the strong evidence. A subset of B-cells in the
peripheral tissues is stimulated to produce anti-AQP4 IgGFigure 2 Comparison of serum apoA-I levels in female among
NMO, ATM patients and healthy control. Black star: HC versus
NMO or ATM; red star: NMO versus ATM. **: p < 0.001.antibody, which results in an extensive loss of astrocytes
in specific regions of the CNS via complement mediated
cytotoxicity [1]. It had been previously confirmed that as-
trocytes could generate apoA-I in rat [21], and the exten-
sive loss of astrocytes resulted in significantly decreased
productions of apoA-I. Moreover, some studies indicated
that apoA-I plasma concentrations was diminished in SLE
and this decrease was associated with the presence of
anti-apoA-I antibodies in 32% of patients [22]. Such
specific anti-apoA-I antibodies are likely to exist in
NMO patients because humoral immunity involved in
the pathological process. In addition, based on a survey
of serum cytokine levels [23], the study indicated that
increased inflammation existed in patients with NMOFigure 3 Comparison of serum apoA-I levels in male among
NMO, ATM patients and healthy control. Black star: HC versus
NMO or ATM ; red star: NMO versus ATM. *: p < 0.01; **: p <0.001.
Figure 4 Influence of corticosteroid treatment on serum apoA-I
levels of patients with NMO. High-dose intravenous corticosteroid
treatment was given to patients with NMO for one week.
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excludethe possibility that patients with NMO have an
increased inflammatory response in comparison to pa-
tients with ATM, resulting in the increased utilization
of apoA-I. Based on the above mentioned reasons, it is
reasonable that patients with NMO might have signifi-
cantly lower serum apoA-I levels than the patients with
ATM as shown in our results. Our results also suggest
that the serum apoA-I levels in NMO might provide
some useful clues for the differential diagnosis against
ATM.
Finally, we found that the serum levels of apoA-I were
lower in males than in females in all the analyzed
groups, though the differences were not statistically sig-
nificant in patients with NMO or ATM. It could be
explained by that apoA-I levels are moderated by estro-
gen levels [24]. However, a correlation between apoA-I
and EDSS score in NMO and ATM patients showed no
statistical differences. This suggested that apoA-I level
was not correlated with disease disability. However, fur-
ther researches are needed to verify this finding with
a larger patient population. Interestingly, the serum
ApoA-I levels were significantly increased after NMO
patients received corticosteroid treatment for one week.
Corticosteroids have anti-inflammatory properties and
immunosuppressive effects that could result in decrease
of the productions of cytokines and stimulated T lym-
phocytes [4], resulting in increased levels of apoA-I after
corticosteroid administration.
In the future, we plan to measure the apoA-I levels in
cerebrospinal fluid of the patients suffered from NMO
and ATM and discuss the relationship between CSF
apoA-I and clinical presentations of NMO and ATM pa-
tients. We also intend to collect more study subjects toseek out more clues to help differentiate these two
diseases at outset.
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